U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06916143) titled 'Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid' on April 02.
Brief Summary: The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: LY4100511
Administered orally.
DRUG: Rabeprazole
Administered orally.
Recruitment Status: NOT_YET_RECRU...